Please assess the completion status of the following clinical trial:

Trial Title: Effect of Cytoreductive Chemotherapy and a CCR5 Coreceptor Antagonist on HIV-1 Eradication

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who give written consent to participate in the study~* Age between 18 and 65 years old, included.~* Chronic HIV-1 Demonstration of R5 viral tropism (use of CCR5 coreceptors) by genotyping in plasma samples stored~* Patients that are to be treated with intensive chemotherapy for non Hodgkin lymphoma With or without stable antiretroviral therapy~* Patients that are able to understand the purpose of the study and be available for scheduled appointments.~* Both in the case of female and male patients, the patient agrees to use a double barrier method of contraception from the moment of signing the informed consent until 3 months after the end of their participation in the study.~Exclusion Criteria:~* To have planned antiretroviral treatment interruption during the participation in the study~* Hypersensitivity to products used in this study~* To be involved in another clinical trial or received an investigational drug within 3 months prior to the study initiation~* To have contraindications or limitations to perform leukapheresis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Control) (Type: NO_INTERVENTION): Patients receiving intensive chemotherapy with/without stable antiretroviral therapy. Patients not receiving antiretroviral therapy will start it.~Patients randomized to this group will not receive clinical trial treatment (neither Maraviroc or Placebo)
- Group 2 (Treatment) (Type: EXPERIMENTAL): Patients receiving intensive chemotherapy with/without stable antiretroviral therapy and Maraviroc.~Patients not receiving antiretroviral therapy will start this theraphy together with Maraviroc.

Based on this trial design, predict the completion outcome and termination type (if applicable).